Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07413991 · ClinicalTrials.gov registry record · NA

Expressive Writing Program Among Young Adults With Blood Cancer

A NA study of Hematologic Malignancy, sponsored by Blood Cancer United.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT07413991: Active NA study of Hematologic Malignancy, sponsored by Blood Cancer United.

NCT07413991 is a NA study of Hematologic Malignancy that is active but no longer recruiting, run by Blood Cancer United. The registered enrollment target is 100 participants, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07413991, a NA study of Hematologic Malignancy, is active but no longer recruiting, sponsored by Blood Cancer United.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness. Participants will * Take part in an online expressive writing workshop for four weeks * Take three surveys at different times over 12 weeks Researchers will compare changes in mental wellness reported by the participants of the workshop to those who will wait four weeks to start the workshop. After four weeks, the participants who are waiting will start their workshop.

Primary Outcome

Participants' mental wellbeing will be evaluated using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS), specifically the original 14-item scale developed by researchers at the University of Warwick and the University of Edinburgh in 2007. This self-report questionnaire asks questions about participants' feelings and how they have been functioning over the last two weeks to capture a comprehensive view of their recent mental wellbeing. Participants will rate each question on a 5-point Liker

Conditions Studied

Interventions

  • BEHAVIORAL Expressive Writing Workshop

Study Locations (1)

District of Columbia

  • Blood Cancer United - Washington D.C.

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-02-01
Est. Completion 2026-09-30
Phase NA
Blood Cancer United

4 total trials

What the registry record for NCT07413991 still lists

NCT07413991 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Expressive Writing Workshop is the first listed.

NCT07413991 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT07413991 about?

NCT07413991 is a clinical study titled "Expressive Writing Program Among Young Adults With Blood Cancer". The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness. Participants will * Take part in an online expressive writing workshop for ...

What is the current status of trial NCT07413991?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-02-01. Estimated completion is 2026-09-30.

What conditions does trial NCT07413991 study?

This clinical trial studies the following conditions: Hematologic Malignancy.

What interventions are being tested in trial NCT07413991?

The interventions under investigation include: Expressive Writing Workshop (BEHAVIORAL).

Who is sponsoring clinical trial NCT07413991?

This trial is sponsored by Blood Cancer United, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07413991 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07413991's enrollment target sits among peer trials

100 11th of 48 higher than 36 of 48 other Hematologic Malignancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07413991, the US trial registry maintained by the National Library of Medicine. NCT07413991 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.